BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhou F, Zhang Y, Xu X, Luo J, Yang F, Wang L, Xie S, Sun J, Yang X. Establishment and characterization of three stable Basal/HER2-positive breast cancer cell lines derived from Chinese breast carcinoma with identical missense mutations in the DNA-binding domain of TP53. Cancer Cell Int 2018;18:118. [PMID: 30140169 DOI: 10.1186/s12935-018-0617-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
Number Citing Articles
1 Shao C, Anand V, Andreeff M, Battula VL. Ganglioside GD2: a novel therapeutic target in triple-negative breast cancer. Ann N Y Acad Sci 2021. [PMID: 34596246 DOI: 10.1111/nyas.14700] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
2 Li Z, Zhuo W, Chen L, Zhang X, Chen C, Hu D, Chen Y, Yang J, Zhou Y, Mao M, Xu L, Ju S, Shen J, Wang Q, Dong M, Xie S, Zhou J, Wang L. Establishment and Characterization of a HER2-Positive Cell Line Derived From the Pleural Effusion of a Drug-Resistant Breast Cancer Patient. Front Cell Dev Biol 2021;9:680968. [PMID: 34141711 DOI: 10.3389/fcell.2021.680968] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Li X, Chen X, Wen L, Wang Y, Chen B, Xue Y, Guo L, Liao N. Impact of TP53 mutations in breast cancer: Clinicopathological features and prognosisImpact of TP53 mutations in breast CA. Thorac Cancer 2020;11:1861-8. [PMID: 32412177 DOI: 10.1111/1759-7714.13467] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]